Kaken Pharmaceutical Co., Ltd. (TYO:4521)

Kaken Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	52,152	44,713	54,093	50,625	59,561	61,025
Short-Term Investments	5,991	5,992	15,992	14,699	14,699	13,599
Cash & Short-Term Investments	58,143	50,705	70,085	65,324	74,260	74,624
Cash Growth	4.95%	-27.65%	7.29%	-12.03%	-0.49%	-3.47%
Accounts Receivable	20,357	19,378	21,178	23,744	19,268	20,260
Other Receivables	3,540	3,370	-	-	-	-
Receivables	23,897	22,748	21,178	23,744	19,268	20,260
Inventory	19,371	19,115	19,020	17,167	15,563	14,980
Other Current Assets	1,646	1,483	1,094	739	812	749
Total Current Assets	103,057	94,051	111,377	106,974	109,903	110,613
Property, Plant & Equipment	27,067	27,134	27,629	25,355	25,498	25,734
Long-Term Investments	18,915	27,373	28,061	29,241	20,312	18,871
Goodwill	5,419	5,399	14,035	-	-	-
Other Intangible Assets	18,954	18,892	5,254	7,462	6,741	8,236
Long-Term Deferred Tax Assets	5,343	5,367	4,065	2,590	3,873	1,725
Other Long-Term Assets	8,659	1	1	1	1	2
Total Assets	187,414	178,217	190,422	171,623	166,328	165,181

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	7,758	7,566	8,322	7,099	6,219	5,939
Accrued Expenses	494	2,590	2,385	1,639	1,561	1,394
Short-Term Debt	3,850	3,850	3,850	3,850	3,850	3,850
Current Income Taxes Payable	3,078	4,558	13,596	4,222	7,828	5,979
Other Current Liabilities	9,448	2,239	2,201	2,214	1,380	1,887
Total Current Liabilities	24,628	20,803	30,354	19,024	20,838	19,049
Pension & Post-Retirement Benefits	4,804	4,716	4,954	6,393	6,349	5,039
Long-Term Deferred Tax Liabilities	4,435	4,405	1,514	1,947	1,771	2,229
Other Long-Term Liabilities	666	675	966	505	535	540
Total Liabilities	34,533	30,599	37,788	27,869	29,493	26,857

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	23,853	23,853	23,853	23,853	23,853	23,853
Additional Paid-In Capital	11,406	11,406	12,932	11,462	11,406	11,406
Retained Earnings	130,448	125,625	135,242	128,506	126,135	126,347
Treasury Stock	-23,776	-23,776	-28,233	-28,613	-30,026	-28,714
Comprehensive Income & Other	10,950	10,510	8,840	8,546	4,889	4,854
Total Common Equity	152,881	147,618	152,634	143,754	136,257	137,746
Minority Interest	-	-	-	-	578	578
Shareholders' Equity	152,881	147,618	152,634	143,754	136,835	138,324
Total Liabilities & Equity	187,414	178,217	190,422	171,623	166,328	165,181

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	3,850	3,850	3,850	3,850	3,850	3,850
Net Cash (Debt)	54,293	46,855	66,235	61,474	70,410	70,774
Net Cash Growth	5.32%	-29.26%	7.75%	-12.69%	-0.51%	-3.65%
Net Cash Per Share	1433.74	1235.92	1735.63	1629.01	1874.05	1863.55
Filing Date Shares Outstanding	37.87	37.87	37.87	37.87	37.47	37.79
Total Common Shares Outstanding	37.87	37.87	38.4	37.87	37.47	37.82
Working Capital	78,429	73,248	81,023	87,950	89,065	91,564
Book Value Per Share	4037.19	3898.19	3974.44	3796.01	3636.14	3642.30
Tangible Book Value	128,508	123,327	133,345	136,292	129,516	129,510
Tangible Book Value Per Share	3393.56	3256.73	3472.18	3598.97	3456.25	3424.53

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 23, 2026

Data Sources Report a data error